RNA | MedPath Search

Found 452 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "RNA"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 2

Completed

Conditions: Stage IV Prostate Cancer
Hormone-resistant Prostate Cancer
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Drug: Hsp90 inhibitor STA-9090
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction
Other: enzyme-linked immunosorbent assay
Genetic: RNA analysis
Other: spectrophotometry
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: gene expression analysis

First Posted Date: 2011-01-05

Last Posted Date: 2018-09-18

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01270880

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
University of Medicine nd Denistry of New Jersey, Piscataway, New Jersey, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Phase 2

Completed

Conditions: Contiguous Stage II Mantle Cell Lymphoma
Noncontiguous Stage II Mantle Cell Lymphoma
Stage I Mantle Cell Lymphoma
Stage IV Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Stage III Mantle Cell Lymphoma

Interventions: Drug: bortezomib
Biological: rituximab
Other: laboratory biomarker analysis
Other: immunohistochemistry staining method
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: DNA analysis
Other: pharmacological study
Other: pharmacogenomic studies
Other: Questionnaire Administration

First Posted Date: 2010-12-29

Last Posted Date: 2023-07-27

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 23

Registration Number: NCT01267812

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine

Phase 2

Completed

Conditions: Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions: Biological: 20 micrograms dose H5 VLP
Biological: 30 micrograms dose H5 VLP
Biological: 45 micrograms dose H5 VLP
Biological: 45 micrograms non-adjuvanted H5 VLP
Biological: Placebo

First Posted Date: 2010-11-19

Last Posted Date: 2012-07-31

Lead Sponsor: Medicago

Target Recruit Count: 255

Registration Number: NCT01244867

Locations: 🇨🇦
Kendle Early Stage, Toronto, Ontario, Canada

Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy

Phase 1

Terminated

Conditions: Stage IV Rectal Cancer
Recurrent Rectal Cancer
Recurrent Colon Cancer
Stage IV Colon Cancer

Interventions: Drug: panobinostat
Drug: fluorouracil
Drug: leucovorin calcium
Procedure: biopsy
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: western blotting
Other: laboratory biomarker analysis
Genetic: gene expression analysis
Genetic: RNA analysis
Genetic: polymorphism analysis

First Posted Date: 2010-11-11

Last Posted Date: 2015-05-27

Lead Sponsor: University of Southern California

Target Recruit Count: 7

Registration Number: NCT01238965

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia

Completed

Conditions: Leukemia

First Posted Date: 2010-10-27

Last Posted Date: 2016-05-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT01229124

Micro-RNA Expression Profiles in High Risk Prostate Cancer

Terminated

Conditions: Prostate Cancer
Radical Prostatectomy

First Posted Date: 2010-10-13

Last Posted Date: 2016-03-03

Lead Sponsor: Wuerzburg University Hospital

Target Recruit Count: 300

Registration Number: NCT01220427

Locations: 🇩🇪
Department of Urology and Pediatric Urology University Hospital Würzburg, Würzburg, Germany

Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma

Phase 1

Terminated

Conditions: Metastatic Melanoma

Interventions: Biological: Vaccination with RNA-transfected mature autologous DC

First Posted Date: 2010-10-07

Last Posted Date: 2015-05-25

Lead Sponsor: Duke University

Target Recruit Count: 2

Registration Number: NCT01216436

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Completed

Conditions: Anaplastic Large Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Mantle Cell Lymphoma
Noncontiguous Stage II Grade 3 Follicular Lymphoma
Noncontiguous Stage II Small Lymphocytic Lymphoma
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Splenic Marginal Zone Lymphoma

Interventions: Procedure: infection prophylaxis and management
Other: laboratory biomarker analysis
Other: flow cytometry
Genetic: DNA analysis
Genetic: RNA analysis
Procedure: management of therapy complications
Drug: ganciclovir
Drug: valganciclovir
Drug: foscarnet sodium
Procedure: antiviral therapy
Genetic: polymerase chain reaction
Genetic: protein expression analysis

First Posted Date: 2010-09-13

Last Posted Date: 2019-04-25

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 153

Registration Number: NCT01199562

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer

Conditions: Ovarian Cancer

First Posted Date: 2010-08-24

Last Posted Date: 2014-12-05

Lead Sponsor: University of Virginia

Target Recruit Count: 103

Registration Number: NCT01187602

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy

Phase 1

Completed

Conditions: Thrombocytopenia
Neoplasm
Cancer

First Posted Date: 2010-07-15

Last Posted Date: 2013-11-15

Lead Sponsor: Midwestern Regional Medical Center

Target Recruit Count: 32

Registration Number: NCT01163110

Locations: 🇺🇸
Midwestern Regional Medical Center, Zion, Illinois, United States